Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

NCT ID: NCT00219583

Last Updated: 2012-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

460 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of efficacy and safety UK-390,957.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ejaculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UK-390,957

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Premature ejaculation as defined by DSM-IV

Exclusion Criteria

* History of erectile dysfunction
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Bondi Junction, New South Wales, Australia

Site Status

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Site Status

Pfizer Investigational Site

Spring Hill, Queensland, Australia

Site Status

Pfizer Investigational Site

Adelaide, South Australia, Australia

Site Status

Pfizer Investigational Site

Malvern, Victoria, Australia

Site Status

Pfizer Investigational Site

Nedlands, Western Australia, Australia

Site Status

Pfizer Investigational Site

Mistelbach, , Austria

Site Status

Pfizer Investigational Site

Salzburg, , Austria

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Victoria, British Columbia, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Oakville, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Montréal, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Brno, , Czechia

Site Status

Pfizer Investigational Site

Hradec Králové, , Czechia

Site Status

Pfizer Investigational Site

Prague, , Czechia

Site Status

Pfizer Investigational Site

Le Kremlin-Bicêtre, , France

Site Status

Pfizer Investigational Site

Lyon, , France

Site Status

Pfizer Investigational Site

Munich, Bavaria, Germany

Site Status

Pfizer Investigational Site

Hamburg, , Germany

Site Status

Pfizer Investigational Site

Hanover, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

Beersheba, , Israel

Site Status

Pfizer Investigational Site

Haifa, , Israel

Site Status

Pfizer Investigational Site

Jerusalem, , Israel

Site Status

Pfizer Investigational Site

Tel Aviv, , Israel

Site Status

Pfizer Investigational Site

Tel Litwinsky, , Israel

Site Status

Pfizer Investigational Site

Milan, , Italy

Site Status

Pfizer Investigational Site

Roma, , Italy

Site Status

Pfizer Investigational Site

Nijmegen, , Netherlands

Site Status

Pfizer Investigational Site

The Hague, , Netherlands

Site Status

Pfizer Investigational Site

Bodø, , Norway

Site Status

Pfizer Investigational Site

Moelv, , Norway

Site Status

Pfizer Investigational Site

Oslo, , Norway

Site Status

Pfizer Investigational Site

Bialystok, , Poland

Site Status

Pfizer Investigational Site

Kielce, , Poland

Site Status

Pfizer Investigational Site

Mysłowice, , Poland

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Barcelona, Barcelona, Spain

Site Status

Pfizer Investigational Site

Sabadell, Barcelona, Spain

Site Status

Pfizer Investigational Site

Madrid, Madrid, Spain

Site Status

Pfizer Investigational Site

Málaga, Malaga, Spain

Site Status

Pfizer Investigational Site

Skövde, , Sweden

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Balcali, Adana, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Samanpazarı, Ankara, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Balçova, İzmir, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Canada Czechia France Germany Israel Italy Netherlands Norway Poland Spain Sweden Turkey (Türkiye)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3871027

Identifier Type: -

Identifier Source: org_study_id